Ocular Therapeutix’s Strategic Positioning and High Success Probability Support Buy Rating

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Ocular Therapeutix, with a price target of $20.00.

Tara Bancroft’s rating is based on several compelling factors that highlight the potential of Ocular Therapeutix’s stock. The upcoming SOL-1 data, expected in the first quarter of 2026, is anticipated to achieve statistically significant results, which could enhance the widespread use of Axpaxli, particularly in the vast wAMD market. The company’s strong patient retention and adherence to protocol criteria, along with the absence of safety concerns, further bolster confidence in the trial’s success.
Moreover, the SOL-1 trial is uniquely positioned as the only known superiority pivotal trial in its field, which could grant Ocular Therapeutix a significant competitive advantage. A superiority label would allow the company to bypass certain market challenges, such as payor-mandated step therapies and pricing pressures from emerging biosimilars. This strategic positioning, coupled with the high probability of success, supports the Buy rating as it suggests a robust future for Axpaxli in the market.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OCUL in relation to earlier this year.